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Viral microarrayOrthopoxviruses encode multiple proteins that modulate host immune responses. We determined whether
cowpox virus (CPXV), a representative orthopoxvirus, modulated innate and acquired immune functions of
human primary myeloid DCs and plasmacytoid DCs and monocyte-derived DCs (MDDCs). A CPXV infection of
DCs at a multiplicity of infection of 10 was nonproductive, altered cellular morphology, and failed to reduce
cell viability. A CPXV infection of DCs did not stimulate cytokine or chemokine secretion directly, but
suppressed toll-like receptor (TLR) agonist-induced cytokine secretion and a DC-stimulated mixed leukocyte
reaction (MLR). LPS-stimulated NF-κB nuclear translocation and host cytokine gene transcription were
suppressed in CPXV-infected MDDCs. Early viral immunomodulatory genes were upregulated in MDDCs,
consistent with early DC immunosuppression via synthesis of intracellular viral proteins. We conclude that a
nonproductive CPXV infection suppressed DC immune function by synthesizing early intracellular viral
proteins that suppressed DC signaling pathways.ollins, CO 80521, USA.
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Orthopoxviruses are a genus of poxviruses that include among
others the virulent human pathogen variola virus (VARV), the agent of
smallpox, as well as monkeypox virus (MPXV), cowpox virus (CPXV)
and vaccinia virus (VACV), the latter two viruses comprising the
original vaccines, which led to the eradication of smallpox. The
success of these vaccines suggests that new vaccines using vaccinia
virus as the vaccine platform may provide protection against anumber of other diseases. Paradoxically, poxviruses such as vaccinia
virus encode a large number of immunomodulatory proteins
including both intracellular and secreted proteins that have the
potential to modify the host responses to the primary orthopoxviral
infection as well as to secondary infections (reviewed by Seet et al.,
2003). Many of these proteins can interfere with the effectiveness of
the viral vaccines, indicating that a better understanding of ortho-
poxvirus interactions with the host immune response will help us to
improve orthopoxvirus vectors for use as viral vaccines.
One mechanism that VACV exploits to modulate host immunity is
to infect dendritic cells (DCs) and inhibit their ability to perform
various innate and adaptive immune functions (Deng et al., 2006;
Drillien et al., 2000; Jenne et al., 2001; Yao et al., 2007). Indeed, among
cells of the immune system, vaccinia viruses preferentially infect
monocytes and DCs (Liu et al., 2008; Sanchez-Puig et al., 2004; Yu et
al., 2009). As innate immune cells, both myeloid DCs (mDCs, also
referred to as conventional DCs) and plasmacytoid DCs (pDCs)
recognize pathogen-associated molecular patterns (PAMPs) using
toll-like receptors (TLRs) and other pattern recognition receptors
(PRRs) and respond by secreting cytokines and chemokines that
412 S.J. Hansen et al. / Virology 412 (2011) 411–425participate in the nonimmune host defense against the pathogen
(reviewed in Kaisho and Akira, 2003). As cells also responsible for
initiating adaptive immunity, DCs avidly take up and process antigen
and, after appropriate perturbation through their pattern recognition
receptors (PRRs), mature and migrate to regional lymph nodes where
they present antigen in the context of MHC class II to stimulate naïve
CD4 T cells to divide and differentiate (reviewed in Lipscomb and
Masten, 2002). Therefore, if an orthopoxvirus infected sufﬁcient
numbers of DCs in vivo, it might be expected to compromise the host's
ability to protect itself against the primary viral infection as well as to
any secondary infectious agent that might challenge the host during
the orthopoxvirus infection.
CPXV naturally infects wild rodents, including mice, and inciden-
tally infects humans (Bennett et al., 1997; Chantrey et al., 1999;
Crouch et al., 1995; Vorou et al., 2008). Cowpox infections in Europe
among younger individuals have been increasingly reported, because
smallpox vaccination is no longer routine (Vorou et al., 2008). The
virus has a larger genome than VACV and encodes more immuno-
suppressive molecules than VACV (Gubser et al., 2004; Meyer et al.,
2002), so we asked whether CPXV, as described for VACV, might
suppress the immune function of human monocyte-derived DCs
(MDDCs). We also, for the ﬁrst time, examined the effect of an
orthopoxvirus infection on primary peripheral blood mDCs and pDCs.
We found that although CPXV infection of DCswas nonproductive and
failed to kill the cells, it profoundly suppressed both innate and
acquired immune function of all three subsets of DCs. Therefore, we
performed additional studies to determine the mechanisms.
Results
CPXV infection of human DCs is not productive and does not alter cell
viability, but does alter cellular morphology
We ﬁrst asked whether CPXV infection of human DCs resulted in
viral progeny (a productive infection) and resulted in eventual lysis of
the cells. CPXV infection of a standard permissive cell line, VeroE6 at a
moi of 10 led to a productive infection with lysis of the monolayer
within 24 h (data not shown). In contrast, infection of MDDCs and
primary mDCs and pDCs resulted in no increase in viral progeny
(Supplemental Fig. 1) and no more cell death at 24 h or 5 d than did
culture inmedium only (Table 1). However, a nonpermissive infection
with orthopoxviruses might still allow for viral DNA replication with
the generation of late protein production, and the production of viral
inclusions such as the production of A-type inclusions (Patel et al.,
1986), even though mature viral assembly does not occur. Further-
more, poxvirus infections have been associated with disruption of the
cell cytoskeleton leading to morphologic changes in the infected cells
(Cudmore et al., 1995; Ward and Moss, 2001). MDDCs from in vitro
culture demonstrated typical dendrites (Fig. 1A), while mDCs andTable 1
CPXV infection of DCs for either 24 h or 6 d does not decrease viable cell recovery.
Time of DC exposure MDDC mDC pDC
% Recovery % Recovery % Recovery
24 h exposure to
Medium 61±16 69±10 80±03
TLR agonist 64±13 68±21 62±15
CPXV 88±06 63±10 69±08
24 h exposure+5 d incubation
Medium 39±13 27±14 51±06
TLR agonist 62±15 46±16 56±06
CPXV 45±10 44±15 57±19
Data is expressed as percent viable cell recovered at 24 h or after a 24 h exposure to
virus+5 additional days of incubation divided by the initial viable DCs placed in culture
with the treatments shown×100±STD. Viability was determined by trypan blue
exclusion.pDCs freshly isolated from peripheral blood exhibited few distin-
guishing features aside from their monocytoid and plasmacytoid
appearances, respectively (Figs. 1B and C.). After overnight culture of
MDDCs, mDCs and pDCs in medium only (Figs. 1D, E, and F,
respectively) or with TLR agonists in medium (Figs. 1G, H, and I),
dendritic projections became more pronounced and punctate cyto-
plasmic vesicles formed in all DCs, characteristics associated with
normal DC maturation. In contrast, DCs treated with CPXV (Figs. 1J, K
and L) did not demonstrate these features of maturation. CPXV-
exposed MDDCs demonstrated more extensive cytoplasmic vacuole
formation and loss of dendrites with the formation of syncytial cells in
up to 20% of the cells (Fig. 1J shows a bi-nucleated MDDC). mDCs
exposed to CPXV demonstrated excessive vacuolation, loss of
dendrites, and, in 24% of the cells, cytoplasmic eosinophilic inclusions,
characteristic of A-type inclusions (Fig. 1K). pDCs exposed to CPXV
formed fewer large vacuoles as compared to mDCs, but also formed
eosinophilic inclusions similar to those in mDCs in 24% of cells
(Fig. 1L). NeithermDCs nor pDCs formed syncytia, whileMDDCs failed
to demonstrate eosinophilic cytoplasmic inclusions. The morphologic
changes were consistent with a nonpermissive infection of all three
DC subsets, with typical A-type inclusions evident in some of the
mDCs and pDCs.
CPXV infection of DCs fails to stimulate cytokine secretion and inhibits
TLR-induced cytokine secretion
An orthopoxvirus infection, even if non-permissive, could allow
synthesis of viral immunomodulatory proteins that might interfere
with DC responses to the infecting virus as well as to exogenous
stimuli. We asked whether CPXV directly interacted with PRRs and
stimulated production of cytokines and chemokines from MDDCs,
mDCs and pDCs. mDCs and pDCs isolated directly from human
peripheral blood and MDDCs generated in culture were incubated for
24 h in medium as a negative control, with appropriate TLR agonists
(as a positive control) or with CPXV. In humans, MDDCs and mDCs
express TLR4 while pDCs strongly express TLR7. Therefore, LPS was
used to stimulate MDDCs and mDCs through TLR4, and inﬂuenza A
was used to stimulate pDCs through TLR7.
CPXV exposure failed to stimulate secretion of any of 23 cytokines
analyzed in initial experiments from any of the DC types (see
Materials andmethods for a complete list). In contrast, LPS stimulated
the secretion of the cytokines IL-1β, IL-6, IL-10, IL-12p40, MIP-1α and
TNFα from MDDCs and mDCs while inﬂuenza A stimulated pDCs to
secrete IFNα, MIP-1α and TNFα. MDDCs, mDCs and pDCs failed to
consistently secrete any of the remaining 23 cytokines tested in
response to their relevant agonist. For simplicity, for MDDCs and
mDCs, we show data for IL-12p40 and TNFα, two cytokines often
produced in response to TLR agonists by mDCs, and MIP-1α, a
chemokine that has phagocyte stimulating and proinﬂammatory
properties (Figs. 2A, B, D, E, G, H). For pDCs, we show data for IFNα, a
hallmark anti-viral response of pDCs,MIP-1α, and TNFα (Figs. 2C, F, I).
The failure of CPXV to induce cytokine secretion might reﬂect either
lack of stimulation or suppression that overrides any stimulatory
effects. Therefore, we asked whether CPXV suppressed the response
to a strong TLR agonist by adding CPXV to DC cultures at the same
time the TLR agonist was added. TLR agonist-induced secretion of all
cytokines by MDDCs, mDCs and pDCs was signiﬁcantly suppressed by
the presence of CPXV in culture (Figs. 2A–I and data not shown).
If DC suppression resulted from the synthesis of viral immuno-
suppressive proteins, it would be expected that live virus would be
required to demonstrate the interference with TLR agonist-induced
cytokine secretion. The virus was heat inactivated (hi) and added to
DC cultures at the same time that the TLR agonist was added. The
hiCPXV did not stimulate cytokine secretion from DCs nor did hiCPXV
suppress TLR agonist stimulated cytokine secretion from MDDCs,
mDCs or pDCs (Figs. 2A–I and data not shown).
Fig. 1.Human DCs exposed to CPXV exhibit altered morphology. MDDCs, mDCs and pDCs were either unexposed (T=0, top row), medium-exposed for 24 h (T=24 h, second row),
TLR agonist-exposed for 24 h (T=24 h, third row, to LPS for MDDCs and mDCs and to inﬂuenza A for pDCs) or CPXV-exposed for 24 h (T=24 h, fourth row). A. MDDCs from in vitro
culture demonstrated typical dendrites and single nuclei. B. Freshly isolated peripheral blood mDCs exhibited few distinguishing features aside from their monocytoid appearances.
C. Freshly isolated peripheral blood pDCs demonstrated a plasmacytoid appearance. D. MDDCs after 24 h culture inmedium demonstrated dendrites relatively unchanged from prior
to overnight culture. E. mDCs after a 24 h culture in medium developed more dendrites F. pDCs after a 24 h culture appeared unchanged. G. MDDCs treated for 24 h with LPS showed
similar dendrite formation, but larger vacuoles as compared to those that were incubated overnight in medium. H. mDCs cultured overnight in LPS showed increased dendrite and
vacuole formation as compared to those incubated in LPS-free medium. I. pDCs cultured with inﬂuenza A showed increased formation of surface projections with some dendrites as
compared to pDCs culture overnight in virus-free medium. J. MDDCs cultured 24 h with CPXV showed blebbing and loss of dendrites with increased numbers of vacuoles. A
subpopulation showed multi-nucleation; shown here is as a bi-nucleated MDDCs. K. mDCs exposed 24 h to CPXV also demonstrated excessive vacuolation, loss of dendrites and
surface blebbing, and, in 24% of the cells, cytoplasmic eosinophilic inclusions, characteristic of A-type inclusions. L. pDCs exposed to CPXV for 24 h formed fewer large vacuoles as
compared to mDCs, but 24% of them contained eosinophilic inclusions similar to those in mDCs. Large arrows identify membrane blebs (J and K); small arrows identify vacuoles
(J and L) and arrowheads identify viral inclusions (K and L). All cells were photographed with a 63× objective.
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CPXV-infected MDDC, mDC and pDC supernatants and for IFNα in
pDC supernatants was that the conditioned medium contained virally
encoded immunomodulators that might interfere with their detec-
tion, i.e., receptors for TNFα (vTNFR), the viral CC chemokine inhibitor
(vCCI) or a receptor for IFNα (Colamonici et al., 1995; Loparev et al.,
1998; Smith et al., 1996; 1997; Symons et al., 1995). Therefore, we
assayed TNFα, MIP-1α and IFNα standards (and IL-6, IL-10 and IL-12
standards as controls) in “conditioned”medium collected from CPXV-
infected MDDCs and pDCs (or in medium from uninfected DCs as a
control) from four different donors for each DC type. Addition of
conditioned medium from MDDCs and pDCs to standards did not
interfere signiﬁcantly with quantitation of TNFα or MIP-1α (Figs. 3A
and B), suggesting that either the relevant secreted viral factors werenot present or that secreted viral products did not interfere with the
assay for human TNFα and MIP-1α in MDDCs and pDCs. However,
both CPXV-infected MDDC and pDC conditioned medium reduced
detection of the IFNα standard by variable degrees depending on the
conditioned supernatant (Figs. 3A and B). Since, in our hands MDDCs
did not secrete IFNα in response to LPS, this interference with
detection of IFNα in CPXV-infected cells was less relevant, but the
suppressed values of IFNα in 24 h supernatants from inﬂuenza A-
treated, CPXV-infected pDCs could have resulted from interference
with detection by a viral IFNα receptor secreted into the cultures.
However, in two of the four samples examined, the percent
suppression of IFNα secretion in the inﬂuenza A-treated, CPXV-
infected pDCs supernatants was greater than the percent interference
by vIFNα of the IFNα standard detection (data not shown). Thus, we
Fig. 2. CPXV infection does not stimulate DC chemokine/cytokine secretion and inhibits DC secretion in response to TLR agonists. Human MDDCs (A, D, G), mDCs (B, E, H), and pDCs
(C, F, I) were exposed to medium only, a representative TLR agonist (for MDDCs and mDCs, LPS; for pDCs, inﬂuenza A, CPXV, CPX+TLR agonist, hiCPXV or hiCPXV+LPS) for 24 h.
Supernatants for all experiments were assayed for the secretion of IL-1β, IL-10, IFNα, IL-6, IL-12p40, MIP-1α and TNFα, but only IL-12p40 (A, B, C), MIP-1α (D, E, F), TNFα (G, H for
MDDCs) and IFNα (I for pDCs) are shown. Data are an average of 7 independent experiments for medium, LPS, CPXV, and CPXV+TLR-agonist treated DCs and 3 independent
experiments for hiCPXV and hiCPXV+TLR agonist-treated DCs. Statistical analysis one-way ANOVA *pb0.05 and **pb0.01. Statistical comparisons were between TLR agonist-
treated DCs and CPXV+TLR agonist-treated DCs.
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secrete TNFα andMIP-1α, and at least in some donors, the virusmight
have at least partly suppressed secretion of IFNα.Fig. 3. Supernatants from CPXV-infected MDDCs (A) and pDCs (B) interfere with the dete
Supernatants were collected, and then incubated in triplicate with a standard containing a
“percent detected MDDCs/pDCs”was derived as pg/ml cytokine/chemokine in infected DC su
Data is the average of 4 experiments±SEM except for MIP-1α for MDDCs where n=3.CPXV infection of MDDCs did not suppress LPS-induced cytokine
secretion at a moi of 0.01 or 0.1, and only variably suppressed
secretion at a moi of 1.0 (data not shown). Thus, it was possible thatction of IFNα. MDDCs (n=4) and pDCs (n=4) were infected with CPXV at MOI 10.
mixture of the following cytokines: IL-10, IFNα, IL-6, IL-12p70, MIP-1α, and TNFα. The
pernatants divided by pg/ml cytokine of standard in uninfected DC supernatants×100.
Fig. 4. DC pre-treated with live CPXV do not stimulate allogeneic CD4+ T cell
proliferation. MDDCs (A), mDCs (B) and pDCs (C) were pretreated with medium only,
CPXV or CPXV+TLR agonist for 24 h, washed and then incubated for ﬁve days with
allogeneic CD4+ T cells. Cells were pulsed with 1 μCi of [3H] thymidine for the last 19 h
of culture. Graphs are representative of four independent experiments. Statistics were
computed using a two-way ANOVA. Statistical comparisons were between medium-
treated DCs and CPXV-exposed DCs and between TLR agonist-treated DCs and CPXV+
TLR agonist-treated DCs.
415S.J. Hansen et al. / Virology 412 (2011) 411–425the DC suppression required direct infection of the majority of
exposed DCs. The virus-encoded cytokine response modiﬁer A
(CrmA), which is an early protein (Pickup et al., 1986), can be
detected in virus-infected cells using a polyclonal rabbit anti-CrmA
antisera. To assess percent infected DCs at the moi that induced
suppression, CPXV was added to MDDCs at increasing moi, incubated
for 6 h and probed by immunoﬂuorescence for the presence of CrmA
(Supplemental Fig. 2 demonstrates both CrmA-positive and negative
cells). The percent CrmA-positive MDDCs was as follows: at a moi 0;
0.0% (SD±0.0%), at a moi 0.01; 3.0% (±0.5%), at a moi 0.1; 7.8%
(±0.8%), at a moi 1.0; 44.0% (±2.5%) and at a moi 10; 90.5% (±5.8%).
Thus, a moi of 10, which was consistently associated with profound
suppression of LPS-induced cytokine secretion of MDDCs, resulted in
infection of most DCs, consistent with the suppression being due to
direct infection rather than an effect of soluble factors secreted by the
infected DCs. We did not speciﬁcally assess CrmA-positive cells in
mDCs or pDCs at a moi of 10, but presume, based on the presence of
viral inclusions in 24% of these cells that this would be minimum
infection rate and based on the nearly uniform morphologic
differences in infected versus uninfected mDCs and pDCs that a 90%
infection rate in the cells would be likely.
CPXV infection of DCs inhibits their stimulation of allogeneic CD4+ T cell
proliferation
The adaptive immune capacity of human MDDCs, mDCs and pDCs
following overnight exposure to CPXV was assessed in a mixed
lymphocyte reaction (MLR).MDDCs incubated inmediumor pretreated
with LPS stimulated allogeneic CD4+ T cell proliferation, and LPS-
exposed DCs typically stimulated greater proliferation than medium-
exposed DCs (Fig. 4A). In contrast, mDCs incubated overnight in
medium without LPS typically promoted greater proliferation than
those pretreatedwith LPS (Fig. 4B). However, neitherMDDCs normDCs
infected with CPXV overnight were capable of stimulating allogeneic T
cells (Figs. 4A and B). Furthermore, LPS added with CPXV to DCs during
the 24 h pretreatment period did not enhance the capability of infected
MDDCs or mDCs to stimulate a MLR (Figs. 4A and B). Although not as
potent as mDCs in stimulating allogeneic T cells, the ability of pDCs to
promote a MLR was also completely suppressed if they were
preexposed to CPXV overnight (Fig. 4C). Both medium-treated and
inﬂuenza A-treated pDCs promoted proliferation of CD4+ T cells, and
adding inﬂuenza to CPXV+pDC cultures during the 24 h pre-exposure
period did not enhance the ability of infected pDCs to stimulate a MLR.
We asked whether live virus was required for suppression of a MLR
usingMDDCs. MDDCs pretreatedwith hiCPXV stimulated aMLR similar
to MDDCs cultured overnight in medium only and MDDCs pretreated
with hiCPXV plus LPS also promoted T cell proliferation comparable to
LPS-preexposed MDDCs (Fig. 4A). Finally, we asked whether the
inability of CPXV-infected DCs to stimulate a MLR resulted from a direct
effect of the virus carried into culture on the responder T cells.
Therefore, we added the number of CPXV virions comparable to the
number that would be carried into culture by CPXV-infected DCs to
CD4+ T cell cultures stimulated with PMA and PHA (data not shown).
There was no effect of the added live CPXV on T cell stimulation
indicating that the failure of DC to stimulate T cells in the MLR was not
due to CPXV infection of T cells.
CPXV infection of DCs inhibits their phenotypic maturation
One explanation for the poorMLR stimulation by DCs infectedwith
CPXV (both with and without LPS co-exposure) was that infected DCs
were unable to increase their expression of co-stimulatory molecules
and HLA-DR.We assessed thesemolecules onMDDCs, mDCs and pDCs
at 0 time and after 24 h exposure to CPXV in the presence or absence
the relevant TLR agonist. We examined MDDCs and mDCs for the
expression of CD80, CD86, CD40 and HLA-DR, and pDCs were examinedfor the presence of CD80, CD86, HLA-DR and BDCA2, the latter known to
decrease on pDCs as they mature (Dzionek et al., 2000). The percent of
CD80 and CD86-positive MDDCs, mDCs and pDCs were signiﬁcantly
decreased between CPXV-exposed and medium-exposed cells and
between CPXV+LPS-exposed and LPS only-exposed cells (Figs. 5A–C).
Although the percentage of HLA-DR-positive MDDCs, mDCs and pDCs
was unaffected regardless of treatment, the mean ﬂuorescence
intensity of HLA-DR was decreased on all three DC types if they were
CPXV-exposed as compared towhen theyweremedium-treated aswell
as if they were CPXV+LPS-treated as compared to LPS-treatment only,
although the decrease did not reach signiﬁcance for the MDDCs
(Figs. 5D–F). The percentage of CD40-positive MDDCs was unaffected
independent of treatment, but for mDCs, there was a signiﬁcant
decrease in the percent CD40-positive mDCs if they were treated with
CPXV as compared to medium exposure only (Fig. 5B). For pDCs, as
expected, BDCA2 on pDCs decreased during overnight incubation with
medium only or in the presence of inﬂuenza A, but incubation with
CPXV suppressed partially the down-regulation (Fig. 5C). Thus, CPXV
infection of DCs generally suppressed the expression of molecules
known to be important in stimulating T cells to respond in a MLR,
although these observations may not fully explain the profound
suppression of T cell proliferation.
CPXV infection of MDDCs inhibits LPS-induced cytokine mRNA synthesis
and nuclear translocation of NF-κB
It was important to begin to dissect the mechanisms of
suppression caused by infecting DCs at a moi of 10. Because our
Fig. 5. CPXV inhibits the expression of maturation markers on DCs. Four-color ﬂow cytometric analysis of HLA-DR and the co-stimulatory molecules CD80, CD86 and CD40 was
performed on untreated MDDCs (A) and mDCs (B) and after overnight incubation with medium, LPS, CPXV and CPXV+LPS. Expression of HLA-DR, BDCA2 and the costimulatory
molecules CD80 and CD86 was performed on untreated pDCs and then following overnight incubation with medium, inﬂuenza A, CPXV and CPXV+inﬂuenza A (C). MFI of HLA-DR
was analyzed on MDDCs (D), mDCs (E) and pDCs (F) under the same conditions as above. Data shown are an average of three independent experiments for untreated DCs and four
independent experiments for all other experimental conditions. Statistical analysis one-way ANOVA *pb0.05, **pb0.01 and ***pb0.001. Statistical comparisons were between
medium-treated DCs and CPXV-exposed DCs and between TLR agonist-treated DCs and CPXV+TLR agonist-treated DCs.
416 S.J. Hansen et al. / Virology 412 (2011) 411–425ﬁndings were similar among all three DC types and MDDCs are more
readily available in sufﬁcient numbers, we used these cells for
subsequent studies. CPXV expresses over 20 immune evasion genes
in permissive cell lines that could contribute either intracellular or
secreted gene products that could potentially suppress DC immune
function. If any or a combination of them would be expected to play a
role, then the MVA strain in which only few immunomodulatory
genes remain intact should not suppress DC function.MVA (moi=10)
was added to MDDCs with and without LPS for 24 h. MVA failed to
stimulate IL-12, TNFα or MIP-1α secretion by MDDCs, and MVA also
failed to suppress the LPS-stimulated cytokine response in MDDCs
(Supplemental Fig. 3). This ﬁnding is consistent with one or more
CPXV genes being responsible for the complete suppression of LPS-
induced cytokine secretion by human DCs.
A number of viral immune evasion genes have been reported to
interfere with NF-κB-dependent transcriptional activation (Haga andBowie, 2005; Oie and Pickup, 2001). We asked whether one
mechanism by which CPXV inhibited LPS-induced cytokine and
chemokine secretion in MDDCs was to prevent cytokine and
chemokine gene transcription and NF-κB nuclear translocation.
MDDCs were exposed to medium, LPS or CPXV+LPS, and total RNA
was extracted at 0, 1, 2, 4, 6, 12 and 24 h post-exposure. Real-time RT-
PCR was performed and the fold-change for TNFα, MIP-1α and IL-12
transcript levels over 0 h was determined. LPS stimulation of MDDCs
led to signiﬁcant induction of these three cytokine transcripts over
24 h as compared to unstimulated control MDDCs (Fig. 6). The TNFα
transcripts in LPS-treated MDDCs peaked at 1 h post-exposure and
remained at an average of 35-fold higher than the 0 h time point with
amarked reduction at 24 h post-exposure (Fig. 6A). Although, CPXV+
LPS co-treated MDDCs also showed an increase in TNFα transcripts at
1 h and 2 h post-exposure, the levels were signiﬁcantly lower than
LPS-treated, but uninfected MDDCs. Similarly, MIP-1α transcripts in
Fig. 6. CPXV infection of MDDCs inhibits LPS-induced cytokine and chemokine mRNA synthesis. MDDCs were exposed to medium, LPS or CPXV+LPS and total RNA was extracted at
times shown. The CT values for TNFα, MIP-1α, IL-12p40 and cyclophilin A or β-actin (endogenous control) transcripts were quantiﬁed by real-time RT-PCR. The data is shown as the
fold-change (2ΔΔCT) for each transcript normalized to cyclophilin A levels and to 0 h of each treatment and is representative of four independent experiments. The kinetics of TNFα
(A), MIP-1α (B) and IL-12p40 (C) transcripts in MDDCs exposed to medium (square), LPS (triangle) or CPXV+LPS (circle with dashed line) are plotted. *p-valueb0.05; **p-
valueb0.01; ***p-valueb0.001, comparing LPS+CPXV-exposed and LPS-treated groups.
Table 2





nuclear NF-κB at 1 h
% MDDCs with
nuclear NF-κB at 2 h
% MDDCs with
nuclear NF-κB at 4 h
LPS 99±0.8 97±1.2a 75b
LPS+CPXV 83±4.3 20±4.9 5±2.0
a MDDCs were exposed to LPS or LPS and CPXV. At the times shown, the cells were
collected in suspension, cytocentrifuged onto glass slides, ﬁxed and stained with rabbit
polyclonal anti-NF-κBp65, and mounted as described in Materials and methods to
counterstain nuclear DNA with DAPI which yields a blue diffuse nuclear ﬂuorescence to
identify the nucleus. For each variable, 100 cells were counted to identify green
ﬂuorescence against a background of blue (see Supplemental Fig. 4 for examples). Data
is expressed as the average±SD for three separate experiments.
b Only one data point was available for this time point.
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with an average of 88-fold higher than 0 h, but the CPXV+LPS treated
MDDCs failed to induce MIP-1α transcripts (Fig. 6B). Finally, the IL-
12p40 transcripts in LPS-treated MDDCs peaked at 6 h post-exposure
with an average 196-fold higher than at 0 h. Although in CPXV+LPS-
treated MDDCs, IL12p40 transcripts were induced, the levels were
signiﬁcantly lower than in LPS-inducedMDDCs (Fig. 6C). Thus, the co-
exposure of MDDC with CPXV+LPS resulted in signiﬁcant suppres-
sion of LPS-induced transcription of all three cytokines as early as 1 h
post-exposure compared to the LPS-treated MDDCs. These studies
were consistent with live CPXV viral particles, early viral transcripts
and/or viral proteins made very early in infection being responsible
for inhibiting viral host cell cytokine/chemokine gene transcription.
Because transcription of TNFα, MIP-1α and IL-12p40 require NF-
κB activation, we asked whether the inhibition of LPS-induced
cytokine transcription by CPXV infection was associated with
suppression of nuclear translocation of NF-κB. MDDCs were exposed
to LPS or CPXV+LPS, incubated for 0, 1, 2 and 4 h and immunostained
to detect whether NF-κB was in the nucleus (Supplemental Fig. 4). At
1 h post-exposure, there was a small difference in the presence of NF-
κB in the nucleus of MDDCs between LPS-treated MDDCs and CPXV
+LPS treated MDDCs (Table 2). By 2 h post-exposure, while NF-κB
was again detected in the nucleus of nearly all LPS-treated DCs, 20% of
CPXV+LPS-treated MDDCs demonstrated nuclear NF-κB. By 4 h,
fewer than 5% of MDDCs treated with CPXV+LPS demonstrated
nuclear NF-κB while the majority of LPS-treated MDDC continued to
demonstrate nuclear NF-κB. These studies demonstrate that CPXV
infection of human DCs disrupts sustained retention of NF-κB in the
nucleus induced in MDDCs by LPS stimulation.
A representative CPXV immune evasion protein, CrmA, is detected in
MDDCs 2 h post infection
We speculated that the inhibition of LPS-induced NF-κB nuclear
translocation and cytokine gene transcription was the result of
accumulation of one or more viral immunomodulatory proteinswithin the cytoplasm. CrmA protein, a viral inhibitor of caspase-1 (Ray
et al., 1992), was readily detected in DC cytoplasm at 6 h post
infection as shown in the study to investigate the number of DCs
infected at various moi (Supplemental Fig. 2). Therefore, we assessed
the time course for expression of CrmA protein in MDDCs at a moi of
10. CrmA was readily detected by western blot 2 h post-infection and
continued to accumulate through a 12 h time course (Fig. 7). The
detection of CrmA by 2 h was compatible with the possibility that
other early viral transcripts of immune evasion genes might be
translated within 2 h and these proteins could interfere with host
cytokine gene transcription.
CPXV transcripts of immunomodulatory genes are present in infected
MDDCs
As shown above, 90% of MDDCs were infected at a viral moi of 10
as determined by the detection of the viral immunomodulatory
protein, CrmA, in the cytoplasm. However, it was important to assess
expression of other immunomodulatory orthopoxvirus genes that
encode proteins more relevant to early interference with signaling
Fig. 7. Intracellular viral immune evasion/virulence gene product detected in MDDCS as
early as 2 h following CPXV infection. Total cellular extracts were prepared from
uninfected DCs or DCs infected with CPXV (moi 10). Proteins were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) on a 12% SDS-PAGE gel and transferred to
nitrocellulose ﬁlters for immunoblot analysis using anti-CrmA polyclonal antibody
(upper panel). The membrane was stripped and β-actin was detected with anti-β-actin
(lower panel, AbCam mouse monoclonal clone 8226 IgG1).
Table 3
Number of CPXV genes with RNA transcripts in human MDDCs 2.5 fold above 0 time
following infection at a moi of 10 as classiﬁed by functional categories.a,b,c
Functional category for genes 0.5 h 1 h 2 h 4 h 12 hd
Transcription 3 16 17 29 27
DNA replication 4 9 9 10 10
Evasion/virulence 20 41 35 43 43
Virion membrane 2 7 7 30 32
Virion core 0 5 7 20 23
Unknown/other/pseudo 24 48 53 69 68
Totals 53 126 128 201 203
a 0 time indicates the low background levels of viral transcripts present in MDDCs
exposed to virus in the cold, brought to room temperature and then immediately
processed to obtain RNA.
b Functional categories are as listed in Assarsson et al. (2008).
c Details for the expression levels expressed in fold changes above 0 time at the ﬁve
time points for individual genes together with the comparable vaccinia virus
Copenhagen andWestern Reserve strain gene designations are shown in Supplemental
Table 1.
d RNAs detected at late times post-infection may correspond to transcripts of late
genes as well as transcripts from late genes that overlap the open reading frames of
early genes without necessarily corresponding to the late expression of these early
genes.
418 S.J. Hansen et al. / Virology 412 (2011) 411–425through a TLR. MDDCs and VeroE6 cells, the latter to control for
transcription of the full repertoire of viral genes, were either
untreated as negative hybridization controls or exposed to CPXV at
a moi of 10. The transcriptomes of CPXV at 0 time (after cell exposure
to virus in the cold followed by warming to room temperature) and
0.5, 1, 2, 4 and 12 h were assessed using a CPXV-speciﬁc microarrays.
All transcripts that were expressed 2.5 fold above 0 time at each of the
time points assessed were identiﬁed and are listed in Supplemental
Table 1 together with the homologous VACV Copenhagen (COP) gene
designation, the putative gene function, the functional gene class and
the fold increase above 0 time. In Table 3, we summarized data from
Supplemental Table 1 to show at each time point the number of genes
expressed at 2.5 fold above 0 time that encoded proteins of one of six
functional classes, i.e., 1) DNA replication, 2) transcription, 3) immune
evasion/virulence (or immunomodulatory), 4) virion core proteins, 5)
membrane proteins and 6) unknown/other. Expression of immune
evasion/virulence genes was already present at 0.5 h (20 genes),
increased by 1 h (40 genes) and continued through 12 h. The genes
expressed (Supplemental Table 1) included those that encode
proteins that could accumulate within infected cells and potentially
either disrupt TLR signaling e.g. CPXV-BR_184/VACV-A46R and CPXV-
BR_190/VACV-A52R (Bowie et al., 2000) or interfere with NF-κB
activation and subsequent nuclear translocation e.g. CPXV-BR_41/
VAVC-K1L (Lynch et al., 2009; Shisler and Jin, 2004). Furthermore,
many expressed genes also encode proteins that are secreted and,
therefore, could exert effects on cells in the microenvironment or
interfere with detection of cytokines or chemokines in supernatants,
such as the viral chemokine inhibitor vCCI (CPXV-BR_03/227) and the
one that we detected, IFN α/β receptor (CPXV-BR_212) (Supplemen-
tal Table 1). The microarray data also demonstrated that many late
genes encoding structural proteins were transcribed in CPXV-infected
MDDCs, although the infection was nonpermissive, compatible with a
block in a productive infection that was post-DNA replication.
Discussion
Orthopoxviruses are complex enveloped dsDNA viruses that
replicate in the cytoplasm in a cell-cycle independent fashion, and
unlike most viruses, largely independent of host cellular mechanisms
(Moss, 2007). Their immunomodulatory genes were acquired via a
process of co-evolution with their relevant host to circumvent the
host immune response to viral infections (reviewed in Bugert and
Darai, 2000; Pickup, 2007; Seet et al., 2003). These viral genes encode
homologs of human cytokines, cytokine receptors, complement
inhibitors, and other protein binding molecules that either function
within the infected host cell or are secreted whereby they can affect
other cells in the microenvironment. In this study, we chose to use
CPXV to determine the effects of orthopoxviruses upon human
MDDCs, because CPXV possesses one of the most extensive sets ofthe accessory genes present in the genomes of the various
orthopoxviruses, suggesting that it may have more extensive control
over DC functions than viruses such as vaccinia virus. Although the
effects of VACV on humanMDDCs has been examined, amore in depth
examination of the immunomodulatory effect of CPXV on human
MDDCs was warranted, particularly in view of continuing zoonotic
infections of humanswith this virus in eastern Europe (Essbauer et al.,
2010; Vorou et al., 2008). Furthermore, it was important to include in
our studies an evaluation of how CPXV affects the immune function of
two additional human DCs, peripheral blood mDCs and pDCs, primary
DCs, which have been infrequently studied in regard to orthopoxvirus
effects on their function, partly because the numbers that can be
isolated from a unit of blood is less than one million of each. mDCs are
closely related functionally and phenotypically to MDDCs, and as
shown in our studies, showed relatively few differences in their
responses to CPXV. One exception was that while there was a trend to
a decrease in the MFI of HLA-DR inMDDCs following a CPXV infection,
the difference was statistically signiﬁcant with mDCs. However, pDCs
are both functionally and phenotypically different fromMDDCs, and it
was important to determine whether an orthopoxvirus might directly
stimulate a strong interferon response and/or suppress their response
to another viral infectious agent that typically induces a strong
interferon response.
We demonstrated that CPXV caused a nonproductive infection in
human MDDCs, mDCs and pDCs, without increasing cell death over
that of uninfected DCs, even over a period as long as 5 d. The virus
failed to productively stimulate PRRs to induce the secretion of
cytokines or chemokines. Furthermore, DCs of all three types did not
respond to a relevant TLR agonist with appropriate cytokine and
chemokine secretion nor stimulate T cells to proliferate if they were
exposed to CPXV at the same time the TLR agonist was added to DCs.
For pDCs, we were unable to determine conclusively whether the
absence of a detectible IFNα response to either CPXV directly or to
inﬂuenza in the presence of CPXV co-exposure resulted from
suppression or was rather the result of secretion of an IFNα
interfering substance into the medium. However, as noted in results,
at least for pDCs from a few donors, the suppressed IFNα response
could not be explained solely as a result of inability to detect this
cytokine. However, infected MDDCs and pDCs from all donors
secreted signiﬁcant amounts of an IFNα inhibitor, and could,
therefore, be expected to globally interfere with IFNα-mediated
antiviral defenses. The failure of CPXV-infected DCs to stimulate an
MLR was associated with a) decreased expression of HLA-DR, CD80
and CD86, essential for effective T cell stimulation and b) changes in
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capacity to interact effectively with responder T cells.
Among the morphological changes that we observed in infected
DCs, themost unexpectedwas the presence of syncytial cells inMDDC
cultures infectedwith CPXV. VACV and CPXV do not induce syncytia at
neutral pH unless conditions favor the inhibition or inactivation of
proteins such as the K2L and A56R proteins that suppress cell fusion
(Brum et al., 2003; Ichihashi and Dales, 1971; Law and Smith, 1992;
Turner and Moyer, 1992; Wagenaar and Moss, 2007; Zhou et al.,
1992); but it is possible that there was insufﬁcient K2L and A56R to
suppress the fusion of MDDCs abortively infected with CPXV. Of note
is that the formation of multinucleated cells (or syncytial cells) by the
fusion of virus-infected cells has been reported for several poxviruses,
including monkeypox virus (Reed et al., 2004), volepox and
raccoonpox viruses (Knight et al., 1992), and ectromelia virus (Harper
et al., 1978).
The failure of DCs to respond directly to CPXV with cytokine
secretion was almost certainly not due to the lack of a PRR to detect
this large dsDNA virus. Various PRRs, including TLR2 (Zhu et al., 2007),
TLR3 (Hutchens et al., 2008), TLR4 (Hutchens et al., 2008), TLR8
(Martinez et al., 2010), TLR9 (Samuelsson et al., 2008), TLR2-6, MDA5,
NALP3 (Delaloye et al., 2009), and AIM2 (Hornung et al., 2009) have
been implicated in host responses to orthopoxviruses. The lack of
PRR-mediated responses to CPXV infection of DCs suggests that CPXV
is capable of either avoiding stimulating PRR or rapidly disrupting PRR
signaling pathways, or both. Support for the reasoning that CPXV
might not stimulate PRR was that hiCPXV failed to stimulate DCs to
secrete cytokines or chemokines. Support for the possibility that PRR
signaling occurred, but was rapidly disrupted, was that exposure to
simultaneous CPXV and a TLR agonist exposure suppressed the DC
response to the agonist. Similarly, it was recently shown that
ectromelia virus (an orthopoxvirus with a genome that is roughly
the same size as CPXV) differs from VACV in being able to evade TLR2
recognition (O'Gorman et al., 2010).
How orthopoxviruses affect DC function has been studied by a
number of investigators, because DCs initiate immune responses that
must occur to control primary natural orthopoxvirus infections, to
prevent new orthopoxviral infections following vaccination and to
develop immunity to tumor antigens or antigens of non-poxvirus
infections agents expressed in orthopoxvirus vectors. VACV and MVA
have been the orthopoxvirusesmost studied in this regard, and rodent
bone marrow-derived DCs and MDDCs derived from human periph-
eral blood monocytes have been the predominant DCs examined. Our
results are consistent with a number of studies that show that an
orthopoxvirus infection of DCs is nonproductive (Bronte et al., 1997;
Chahroudi et al., 2005; Deng et al., 2006; Drillien et al., 2000;
Engelmayer et al., 1999; Jenne et al., 2000; Liu et al., 2005). Some of
these studies determined that early viral proteins were synthesized in
DCs, but late proteins were not (Drillien et al., 2000; Jenne et al.,
2000). We found that some late genes were transcribed, but we did
not assess whether any proteins were produced. However, the
presence of viral inclusions suggests that at least in mDC and pDC,
there might have been translation of the late ATI protein (Osterrieder
et al., 1994; Patel et al., 1986). Infection by canarypox virus, VACV or
MVA ofMDDCs leads to DC apoptosis (Brandler et al., 2010; Chahroudi
et al., 2006; Zhang et al., 2007), and VACV infection of MDDCs leads to
loss of viability as measured by trypan blue exclusion (Engelmayer et
al., 1999). In contrast, we found that the numbers of viable DCs
(assessed by trypan blue exclusion), was not altered by CPXV
infection (Table 1). Early in our studies, we determined by TUNEL
assay that LPS or CPXV treatment of MDDCs resulted in a small
percentage, although equivalent, of apoptotic cells (data not shown),
suggesting that CPXV in DCs might generate particular strong anti-
apoptotic mechanisms. As regards the effect of an orthopoxvirus
infection on cytokine secretion by DCs, comparable to our studies, a
VACV infection of a murine Langerhans cell line failed to inducecytokine secretion and suppressed the ability of these cells to secrete
cytokines in response to LPS (Deng et al., 2006). In another study,
VACV-infected human MDDCs failed to secrete cytokines (Drillien et
al., 2004), but whether LPS-induced cytokine secretion was sup-
pressed in infected cells was not tested. In general, our ﬁndings that
infection of DCs at a moi of 10 CPXV suppresses maturation of
immature DCs and their ability to stimulate T cells responses are
similar to the ﬁndings of others with VACV (Engelmayer et al., 1999;
Bonini et al., 2001; Jenne et al., 2000; Li et al., 2005;Wang et al., 2009).
One study demonstrated that VACV abortively infected both imma-
ture MDDCs and mature MDDCs, inhibited immature MDDC matura-
tion in the present of monocyte-conditioned medium and suppressed
DC-induced T cell responses (Engelmayer et al., 1999). Another study
demonstrated that VACV suppressed not only suppressed LPS-
induced maturation of immature MDDCs and their ability to stimulate
T cells, but also DC maturation initiated by CD40L, TNFα and polyI:C
(Bonini et al., 2001). We did not assess the effect of CPXV on mature
DCs, but mature DCs are more resistant to VACV infection (Engel-
mayer et al., 1999), and infected mature DCs can be engineered to
present agent for more effective antigen-induced stimulation of T cell
responses (Bonini et al., 2001). We could not ﬁnd any studies that
directly examined how CPXV affected human DCs, but an interesting
study strongly suggested that as compared to VACV, CPXV markedly
inhibitedMHC class I antigen presentation in both human andmurine
antigen presenting cells (Dasgupta et al., 2007). Thus, our studies are
valuable in expanding our understanding of orthopoxviral–DC
interactions to include a comprehensive examination of CPXV on
human MDDCs as well as to more completely determine how an
orthopoxvirus affects human mDC and pDC cytokine and chemokine
secretion or stimulation of an MLR. As regards prior studies on human
DCs and pDCs, one study noted that human peripheral blood
monocytes, B cells, mDCs and pDCs were preferentially infected by
VACV and at a moi of 10, 52% of mDCs and 62% of pDCs were infected
(Chahroudi et al., 2005), but the functional outcomes of this infection
were not assessed. A recent study in mice showed that a VACV
infection of pDCs (generated from bone marrow) at a lower moi of 1
resulted in NF-κB activation and type I IFN production by TLR8
recognizing viral poly (A)/T DNA (Samuelsson et al., 2008). However,
whether directly infected pDCs were the cells that secreted the type I
interferons or whether the secretions was from neighboring unin-
fected cells recognizing non-infectious virions was not assessed.
We were interested in the possible mechanisms by which CPXV
suppressed MDDC maturation and function, because MDDCs were
more readily acquired in sufﬁcient numbers for the designed
experiments than mDCs and pDCs. We found that following
simultaneously addition of CPXV and LPS to MDDCs, NF-κB nuclear
translocation and host cytokine gene expression were inhibited
within 1–2 h. We also demonstrated that MVA, a VACV mutant
missing many of the immunomodulatory genes possessed by CPXV,
did not stimulate cytokine or chemokine secretion by MDDCs nor
suppress their LPS-stimulated cytokine and chemokine secretion.
Finally, we demonstrated that CPXV-infectedMDDCs transcribed over
40 genes that encoded both intracellular and secreted proteins with
possible immunomodulatory function. We interpret these ﬁndings to
indicate that within 1–2 h MDDCs, and probably mDCs and pDCs,
suppress both CPXV-induced and TLR-induced innate immune
function as a result of the accumulation of early viral gene products
on TLR-induced signal transduction and NF-κB dependent transcrip-
tional activation. Consistent with this interpretation, CPXV has been
shown to interfere with the activation of NF-κB transcription factors
in various other cell types (Oie and Pickup, 2001), partly through
expression of CPXV proteins such as CP77 (Chang et al., 2009; Lynch et
al., 2009), and CPXV006 (Mohamed et al., 2009b), as well as partly
through the expression of a variety of viral proteins including CPXV
homologs of the following VACV proteins: A46R and A52R, which
interfere with signaling of TIR-domain containing receptors such as
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with components of the canonical NF-κB signaling pathway (Chen et
al., 2008; DiPerna et al., 2004; Gedey et al., 2006; Shisler and Jin,
2004). These were the CPVX genes CPXV-BR_40, 41, 190, and 208
(M2L, K1L, A52R, and B14R homologs, respectively) detected at 0.5 h
and CPXV-BR_37, and 184 (N1L and A46R homologs, respectively)
detected at 1.0 h. Inhibition of NF-κB activation not only suppresses
cytokine and chemokine secretion, but also affects the expression of
surface molecules essential for effective DC stimulation of the MLR.
NF-κB is a transcriptional regulator for the co-stimulatory molecules
CD80 and CD86 (Ardeshna et al., 2000), and the viral inhibition of NF-
κB activation may contribute to the reduction in these co-stimulatory
molecules on the surface of DCs exposed to CPXV. Transcriptional
regulation of HLA-DR is mediated by the master co-activator protein
MHC class II transactivator protein (CIITA), but promoter–reporter
assays demonstrate that NF-κB directly induces HLA-DR promoter
activation in response to LPS (Lee et al., 2006). Thus, the potential
interference by at least eight CPXV intracellular proteins of signaling
upstream of NF-κB activation may provide an explanation for the
absence of perceived signaling by CPXV to activate DCs, the
suppression of TLR-agonist induced cytokine secretion and the
decreased expression of critical accessory molecules involved in DC-
induced T cell stimulation. Secreted CPXV proteins, such as the CrmB,
CrmC, CrmD viral receptors for TNF (Hu et al., 1994; Loparev et al.,
1998; Smith et al., 1996), as well as secreted receptors for IL-1β
(Spriggs et al., 1992), IL-18 (Born et al., 2000; Smith et al., 2000) and
CD30L (Panus et al., 2002) would also be expected to suppress NF-κB
activation by external ligands, although we were unable to consis-
tently demonstrate that supernatants of CPXV-infected MDDCs were
capable of suppressing LPS-stimulated cytokine and chemokine
secretion. We considered what the role of general suppression of
host gene expression might be on the loss of infected DC function
described here. Unless infection resulted in rapid virus-induced
inhibition of total host and viral protein synthesis, such as can occur
in some non-permissive cells (Drillien et al., 1978), broad suppression
of host gene expression usually does not occur until several hours
after infection, and is frequently incomplete until the onset of viral
late gene expression (Moss, 2007). Thus, it seems to us that uniform
shutdown of protein synthesis doesn't adequately explain the loss of
DC functions, but are better attributed to inhibitors of: TLR/IL-1
signaling pathways (Bowie et al., 2000; Harte et al., 2003; Stack et al.,
2005); NF-kappaB signaling pathways (Chang et al., 2009; Chen et al.,
2008; DiPerna et al., 2004; Graham et al., 2008; Lynch et al., 2009;
Mohamed et al., 2009a; 2009b; Oie and Pickup, 2001; Shisler and Jin,
2004; Tait et al., 2000); caspase-1 and inﬂammasomes (Johnston et
al., 2005; Ray et al., 1992); and the presentation of antigens by MHC
classes I and II (Alzhanova et al., 2009; Boshkov et al., 1992; Byun et
al., 2009; Byun et al., 2007; Dasgupta et al., 2007; Li et al., 2005; Wang
et al., 2009).
The CPXV-induced downregulation of HLA-DR, CD80 and 86would
predictably reduce the capacity of DCs to stimulate allogeneic T cells
proliferation, but likely not completely abrogate the MLR as was
shown in Fig. 4. However, the morphologic changes in CPXV-infected
DCs shown in Fig. 1 are compatible with the virus inducing
cytoskeletal abnormalities that have been shown to interfere with
effective DC-T cell physical interactions (Al-Alwan et al., 2001).
Several studies verify that VACV induces signiﬁcant morphological
changes in the infected cells. VACV infection induces early blebbing
that is associated with macropinocytosis of the virion (Mercer and
Helenius, 2008). VACV also induces cell motility and cytoskeletal
rearrangements, affecting both microﬁlaments and microtubules
(Mercer and Helenius, 2008; Sanderson et al., 1998a, 1998b;
Sanderson and Smith, 1998; Sanderson et al., 1998b; Schramm et
al., 2006). Within 0.5 h of infection of MDDCs, we detected transcripts
of the CPVX-BR_59 gene, a homolog of the VACV gene F11L, which
plays a role in early actin remodeling and induction of motility byfacilitating cell detachment in VACV-infected cells (Mercer and
Helenius, 2008). At least one study has shown that if cortical actin
of DCs was disrupted by transfections with Cdc42 and Rax1 dominant
negatives, the interaction of DCs and CD8+ T cells was ineffective
(Jaksits et al., 2004). Therefore, it seems possible that morphologic
changes in DCs induced by CPXV infection could have interfered with
development of the normal intimate physical interaction between T
cells and DCs that leads to the development of the immunological
synapse needed for a productiveMLR. Thus, themorphologic changes,
in addition to the decrease in surface expression of HLA-DR, CD80 and
CD86 could explain the profound suppression of the MLR.
Our studies as well as those of others agree that orthopoxvirus
infection of DCs compromises their ability to initiate both an innate
and an acquired immune response to the virus, but we found that this
correlated with a very high infection rate of MDDCs. In vivo, the
likelihood that all DCs become simultaneously infected is highly
unlikely, except perhaps at sites of severe infection. For example, in an
intravenous infection of mice, fewer than 2% of splenic dendritic cells
were infected (Yammani et al., 2008). Therefore, how are studies that
show orthopoxviruses markedly depress DC function relevant to
understanding natural orthopoxvirus infections or vaccination? We
believe that virus-induced immunomodulation of infected DCs is
relevant even while other DCs in the infected environment continue
to function. We would predict that a virus capable of suppressing the
functions of infected DCs would initiate qualitatively and quantita-
tively impaired innate and acquired immune responses to infection in
comparison to a virus incapable of suppressing the functions of any
DCs. First, because infected DCs retain an immature DC status with
limited ability to present antigens, they might have the effect of
tolerizing naïve T cells as well as failing to stimulate a protective
immune response in both naïve and memory T cells. One issue is how
quickly infected DCs might become unable to present antigen
effectively to naïve T cells in an infected draining lymph node.
Although some of the data presented involves a 24 h infection of DCs,
the data also show that within only a few hours of infection the
following occur: 1) the expression of early and late viral genes; 2) the
inhibition of transcription of various cytokines, and 3) the inhibition
of ligand-induced accumulation of NF-κB within the nucleus, which
would suggest that the infected DCs are unable to interact with T cells
to yield a productive immune response within hours of infection.
However, for DCs that become infected in the periphery early in an
infection, there is a time frame required for the infected DCs to reach
draining lymph nodes before they can stimulate naïve T cells; this has
been shown to occur over a period of several days in the lungs
following deposition of a non-replicating antigen (Xia et al., 1995).
Indeed, as discussed above, the cytoskeletal rearrangements in
infected cells might preclude the emigration to draining nodes. Still
these paralyzed DCs in the periphery would not be expected to
present antigen to any virus speciﬁc memory T cells that should arrive
at the site of infection. Second, in view of the ability of DCs tomaintain
long-term viability in vitro despite being infected, these cells could
serve in vivo as sources of immune regulating virokines for a
protracted period, which would be beneﬁcial to the virus. For
example, secreted viral products such as INFαR would be expected
to affect the development of an immune response generated by
uninfected DCs, because INFα can enhance the ability of these cells to
stimulate CD4 cells to develop into Th1 cells (Kadowaki et al., 2000).
In sum, with a quantitative loss of immunocompetent DCs and the
ability of infected DCs to secrete immunomodulatory proteins, we
suspect that the result of the infection of a subset of DCs, even if small,
would be to compromise a full immune response. This modulated
response would be less able to curtail the proliferation of the virus,
whichwould give the virus an edge over the host. However, if the host
were able to eventually mount an effective response, then the
infection would end with the host having successfully developed
immunity against future orthopoxvirus infections. An advantage to
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longer period of effective replication and, therefore, opportunity to re-
infect another host. The possible advantage to the host of a modiﬁed
immune response is to retain antigen longer to result in a more
prolonged memory response, once the infection is resolved.
One can extend the discussion to suggest why CPXV and VACV
were both effective vaccines, yet were risky for immunosuppressed
individuals. The moi per DCs following vaccination might be very high
at the local site, but would decrease as the distance from the
inoculation site increased. Effective vaccination could still occur
despite early “paralysis” of local DCs. Indeed, this lack of function
accompanied by secretion of immunomodulators of innate function
might allow for more extensive viral replication with associated
increased antigen load. Uninfected DCs and sinusoidal APCs present in
lymph nodes draining the site of early infection should be capable of
taking up viral particles or peptides and effectively presenting them to
responder T cells and B cells. Any poxvirus containing apoptotic or
necrotic cells would be effectively cross-presented by uninfected DCs
to induce IFNγ secreting and cytotoxic CD8 T cells (Larsson et al.,
2001). The ensuing immune response would then be expected to
eventually control viral replication. Yet, in immunocompromised
hosts in whom the uninfected immune cells are also compromised, or
in those in whom skin lesions allow for continuous self-inoculation,
VACV vaccination would be expected to be associated with early
greater viral replication and more extensive DC infection than in the
immunocompetent host. MVA vaccination is associated with many
fewer side effects, and, as shown in our studies, even a high rate of DC
infection should have little effect on their immune function, at least as
measured by their ability to secrete cytokines and chemokines when
stimulated by LPS. Therefore, even though replication at the
vaccination site would not occur to increase the antigen load as it
might for a CPXV or VACV vaccination, all DCs present should be
capable of presenting viral antigens.
Although we now have an effective vaccine to prevent smallpox or
other emerging orthopoxvirus infection if needed, it remains
important to more fully understand how orthopoxviruses cause
disease and modulate immune function, particularly as long as
sporadic infections with these viruses continue to occur and they
are explored as potential vehicles for development of new vaccines.
Conclusions
Our studies demonstrated that the orthopoxvirus, CPXV, failed to
stimulate cytokine and chemokine secretion in MDDCs, mDCs and
pDCs and profoundly suppressed their immune function as shown by
the infected DCs being unable to secrete cytokines and chemokines in
response to known TLR agonists and also being unable to stimulate a
MLR. The suppression was associated with a nonproductive infection,
without loss of DC viability. In an effort to understand the
mechanisms, we found that viral immunomodulatory genes were
transcribed early in MDDC infection and was associated with the
inhibition of NF-κB nuclear translocation and synthesis of cytokine
and chemokine transcripts. In support of a role for the immunomod-
ulatory genes in suppressing DC function was that MVA, which has a
markedly reduced number of these intact genes, failed to suppress
cytokine and chemokine secretion in LPS-stimulated MDDCs.
Materials and methods
Virus preparation
CPXV strain Brighton Red was grown in VeroE6 cells and puriﬁed
as described by Joklik (Joklik, 1962). Heat-inactivation (hi) of CPXV in
some experiments was performed in a heat block at 57 °C for 45 min
(Harper et al., 1978). Plaque forming assays were performed onVeroE6 cells to demonstrate that this treatment reduced the infectious
units by at or greater than 1,000,000 fold.
Competitive binding assay
1.5×105 VeroE6 cells were grown on a monolayer in a 48-well
plate and 1.5×106 hiCPXV virions were added to each well. Live CPXV
virions were added in 10-fold dilutions beginning with 1500 PFU, and
plaques were allowed to form for 24 h.
Virion carryover
To determine carryover of infectious virions into MLR cultures that
might directly affect the T cell responder, MDDCs were cultured
overnight in 200 μl samples in 96-well plates (125,000 cells/ml) with
CPXV at a multiplicity of infection (moi) of 10 (CPXV PFU per DC) and
washed twice in PBS. The pellet was ﬂash frozen in liquid nitrogen
twice, resuspended in 100 μl complete DMEM with 2.5%FBS, and viral
titer assessed by plaque assay on Vero E6 cells.
Modiﬁed virus Ankara (MVA)
MVA was obtained from the Biodefense and Emerging Infections
Research Resources Repository, Manassas, VA 20108-4137.
MDDC generation
Monocyte puriﬁcation was performed as described with minor
modiﬁcations (Chomarat et al., 2003; Mentzer et al., 1986). Brieﬂy,
buffy coats of human blood (United Blood Services; Albuquerque,
NM) were separated on Ficoll-Paque Plus (GE Healthcare; Uppsala,
Sweden). The mononuclear fraction was allowed to form aggregates
at 4 °C and pelleted and then layered over FBS and pelleted again at
4 °C. Monocyte-enriched aggregates were washed twice in versene
buffer [0.6 mM EDTA in PBS (Gibco; Grand Island, NY)] to disrupt
aggregates and resuspended in a small volume of staining buffer (2%
FBS/2 mM EDTA in PBS). Monocytes were further enriched though a
process of negative selection with magnetic beads labeled with
antibodies to CD3, CD16, CD19 and CD56 (Miltenyi Biotec; Auburn,
CA) to remove contaminating T cells, PMNs, B cells and NK cells,
respectively. Puriﬁed monocytes were seeded into 10 cm culture
dishes at 2–3×106 cells/ml in complete RPMI [RPMI 1640 supple-
mented with 2 mM L-glutamine, 1 mM nonessential amino acids,
1 mM sodium pyruvate, 100 U/ml penicillin and 100 μg/ml strepto-
mycin with 10% heat inactivated FBS and beta-mercaptoethanol (β-
ME)]. IL-4 (20 ng/ml) and GM-CSF (100 ng/ml), both from Biosource/
Invitrogen (Carlsbad, CA), were added at 0 time and on day 3, and on
day 6 monocyte-derived DCs (MDDCs) were harvested for in vitro
studies. MDDCs were cultured in complete RPMI for all experiments.
mDC and pDC isolation
Human mDCs and pDCs were separated based on the differential
presence of CD11c and CD123, respectively, and the absence of all
lineage markers for non-DC lineage cells (Masten et al., 2006). mDCs
co-express CD11c and HLA-DR, and may or may not express CD123
(Liu et al., 2001; O'Doherty et al., 1994). Plasmacytoid DCs (pDCs) co-
express CD4, CD123 and HLA-DR, but not CD11c (Bauer et al., 2001;
Siegal et al., 1999). PBMCs were obtained as described above. Anti-
CD3, CD14, CD16, CD19, CD56 and Glycophorin A coated magnetic
beads (Miltenyi Biotec) were added to PBMCs, which were then
magnetically sorted on an AUTO Macs (Miltenyi Biotec), and the
unlabeled fraction was collected. For FACS sorting, the negative
fraction frommagnetic sortingwas labeledwith ﬂuorescent Abs; i.e., a
mix of CD3, CD14, CD16, CD19, CD20, CD56-FITC (lineage markers);
CD123-PE, HLA-DR-PerCP, and CD11c-APC (BD Pharmingen; San Jose,
CA). Unstained and single-stained (compensation) controls were used
to set gates on the MoFlo (Dako Cytomation; Ft. Collins, CO). Gates
were set to include DCs based on the absence of lineage markers
422 S.J. Hansen et al. / Virology 412 (2011) 411–425(lineage-) and the presence of HLA-DR. mDCswere sorted as CD11c+,
CD123−, and pDCs as CD11c−, CD123+. mDCs were cultured in
complete RPMI, and pDCs were cultured in cRPMI and 10 ng/ml IL-3
(R&D Systems; Minneapolis, MN).
DC viral and TLR agonist exposure
Cells were plated in cell appropriate medium, at a concentration of
1.25×105 cells/ml in triplicate for each treatment. Treatments
included medium (mock), LPS (lipopolysaccharide from Escherichia
coli 0111:B4; Sigma-Aldrich, at a ﬁnal concentration of 1 μg/ml), CPXV
[multiplicity of infection (moi) of 10] and inﬂuenza A/PR/8/34 H1N1
(Advanced Biotechnologies Inc. Columbia, MD) (moi 10). The CPXV
moi 10 was determined to be an appropriate dose in preliminary
titration studies that examined moi of 1, 10 and 100. A CPXV moi of 1
did not suppress the TLR agonist response as completely as amoi of 10
or 100. Suppression was not different between a moi 10 and 100. The
inﬂuenza A moi of 10 was determined as appropriate to stimulate
pDCs based on previous studies (Diebold et al., 2004) and conﬁrmed
in our laboratory. Cells were incubated at 37 °C, 5% CO2 in a
humidiﬁed incubator for 24 h.
Morphologic studies
Cytospins were made of MDDCs freshly isolated from cultures;
freshly sorted mDCs and pDCs; MDDCs, mDCs and pDCs cultured 24 h
in medium; TLR agonist-stimulated MDDCs (LPS), mDCs (LPS) and
pDCs (Inﬂuenza A) in culture 24 h; and MDDCs, mDCs and pDCs
cultured 24 h with CPXV. Cytospins were allowed to dry overnight,
stored at−80 °C or ﬁxed and stained with Diff-quick (Dade Behring;
Deerﬁeld, IL).
CrmA immunostaining
MDDC cytospins were treated with methyl alcohol for 10 min at
20 °C and incubated at 4 °C overnight or at room temperature for 2 h
in a humidiﬁed chamber with a rabbit polyclonal anti-CrmA antibody
(1:5000 dilution), washed ×3 for 10 min in 2 mM EDTA in PBS pH 7.4
and incubated in a humidiﬁed chamber with Alexa Fluor® 488
conjugate goat anti-rabbit IgG (H+L) [Molecular Probes (Invitrogen)
Carlsbad, CA] at a concentration of 0.2 μg/ml for 1 h at 37 °C protected
from light. Slides are mounted in ProLong® Gold antifade reagent
with DAPI from Molecular Probes (Invitrogen) which stains the
nucleus and emits blue and then cover-slipped. Epiﬂuorescence
images were examined and photographed on a Zeiss Axioskop
Epiﬂuorescence Microscope equipped with Zeiss Axiocam HR digital
color camera at a magniﬁcation of 63× using both the DAPI and FITC
ﬁlters. SlideBook software (Intelligent Imaging Innovations; Denver,
CO) was used to merge images and set compensation controls.
NF-κB immunostaining
MDDCs were co-incubated for 0, 15, 30, 60, 120 and 240 min with
LPS or CPXV and LPS. Cytospins were prepared as described for CrmA.
Prepared cytospins were incubated in a humidiﬁed chamber with a
rabbit polyclonal anti-NF-κBp65 antibody — ChIP Grade (ab7970)
(Abcam, Cambridge, MA, USA). 1:2500 dilution of the primary
antibody resulted in optimal staining. Slides were incubated at 4 °C
overnight or at room temperature for 2 h. Slides were washed three
times for 10 min in 2 mM EDTA in PBS 7.4 pH. The slides were then
incubated in a humidiﬁed chamber with Alexa Fluor® 488 conjugate
goat anti-rabbit IgG (H+L) (Molecular Probes (Invitrogen) Carlsbad,
CA, USA) at a concentration of 0.2 μg/ml for 1 h at 37 °C protected from
light. Slides were mounted and epiﬂuorescent images were visualized
as described for CrmA staining above. Replicate slides were prepared
for each variable and at least 100 cells were examined for each slide to
identify where green ﬂuorescence overlapped the nuclei of each cellas amanifestation of NF-κB nuclear translocation (Supplemental Fig. 2
shows examples of cells with and without nuclear staining for NF-κB.)
Cytokine and chemokine secretion
2.5×104 cells were stimulated overnight in 200 μl complete RPMI
in 96-well round-bottom plates. MDDCs and mDCs received the
following treatments: mock (medium only), LPS, CPXV or CPXV+LPS.
pDCs received the following treatments: mock, inﬂuenza A, CPXV, or
CPXV+inﬂuenza A. At 24 h, supernatants were collected and stored
at −70 °C without removal of viral particles. Multi-analyte proﬁling
was performed using the Luminex LX100 system (software version
1.7) with the XY Platform (Luminex). Acquired ﬂuorescence data
were analyzed using StatLia from Brendan Scientiﬁc (version 3.2). In
initial experiments supernatant concentrations of cytokines (IL-1α,
IFNα, IL-12p40, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, IFNγ
and TNFα) and chemokines (RANTES, eotaxin, MIP-1α, MIP-1β, MCP-
1, GROα, MCP-2, MCP-3 IP-10 andMIG)were measured by combining
single bead kits for IL-1α, IFNα, and IL-12 p40 with a 10-plex cytokine
panel and a 10-plex chemokine panel (Biosource; Camirillo, CA or
Upstate Biosciences, Charlottsville, VA). Subsequent experiments
assessed supernatants for the presence of IL-1β, IL-10, IFNα, IL-6, IL-
12p40, MIP-1α and TNFα, because these cytokines and chemokines
were consistently secreted by MDDCs, mDCs or pDCs in response to
the relevant TLR agonist (LPS forMDDCs andmDCs and inﬂuenza A for
pDCs). IL-8 tended to be secreted at high levels regardless of stimulus.
Mixed leukocyte reaction (MLR)
MDDCs were harvested 24 h after overnight incubation in medium
or in medium plus LPS, CPXV, and CPXV+LPS, heat-inactivated (hi)
CPXV or hiCPXV+LPS. mDCs were harvested 24 h after overnight
incubation in medium only or in medium plus LPS, CPXV or CPXV+
LPS; and pDCs were harvested 24 h after overnight incubation in
medium or in medium plus inﬂuenza A, CPXV or CPXV+inﬂuenza A.
PBMCs from the buffy coat of peripheral blood were obtained as
above, and CD4+T cells obtained by negative selection using a human
CD4+ T cell isolation kit II with an AUTO Macs magnetic cell sorter
(Milteny Biotec Inc; Auburn, CA). Graded dilutions of DCs were added
to 1.5×105 allogeneic CD4+ T cells in triplicate in complete medium
to ﬂat-bottomed 96-well plates. After 5 d, cultures were pulsed with
1 μCi of [3H]thymidine for the last 19 h of culture, harvested with a
PHD cell harvester (Cambridge Technologies; Lexington, MA), and
radioactive counts were read on a LS6500 scintillation counter
(Beckman/Coulter; Fullerton, CA). The results are expressed as counts
per minute (cpm)±SD of triplicate wells.
Four-color immunophenotyping
Suspensions of puriﬁed MDDCs and mDCs were incubated with
FcR blocking reagent (Miltenyi Biotec) and stained with the mAbs
anti-CD14-FITC (M5E2, mouse IgG2a), anti-HLA-DR-PerCP (L243,
mouse IgG2a), anti-CD11c-APC (B-ly6, mouse IgG1) and a PE-
conjugated mAb for surface molecule expression or controls as
follows: anti-CD86 (IT2.2, mouse IgG2b), anti-CD80 (L307.4, mouse
IgG1), anti-CD40 (5C3, mouse IgG1), mouse IgG1 (MOPC-21), mouse
IgG2b (27–35) or with biotinylated CD205 (DEC205) (MG 38, mouse
IgG2b, eBiosciences, San Diego, CA), mouse IgG2b (ebmG2b, eBios-
ciences), followed by streptavidin-PE for detection. Suspensions of
pDCs were treated with FcR blocking reagent and stained with the
mAbs anti-CD14-FITC (M5E2, mouse IgG2a), anti-HLA-DR-PerCP
(L243, mouse IgG2a), anti-CD123-PE (9F5, mouse IgG1), and an
APC-conjugated mAb for the surface molecules expression or controls
as follows: anti-BDCA-2 (AC144, mouse IgG1; Miltenyi Biotec), anti-
BDCA-4 (ADS-17F6, mouse IgG1, Miltenyi Biotec), mouse IgG1
(MOPC-21) or mouse IgG2b (27–35). Biotinylated anti-CD80
423S.J. Hansen et al. / Virology 412 (2011) 411–425(L307.4, mouse IgG1) and biotinylated anti-CD86 (IT2.2, mouse
IgG2b) was detected by adding streptavidin-APC. One set of cells
was stained with antibody controls i.e., mouse IgG2a-FITC (G155–
178), mouse IgG2a-PerCP (×39), and mouse IgG1-APC (MOPC-21) to
set the appropriate gates by ﬂow cytometry. All Abs were purchased
from BD Biosciences unless otherwise noted. Cells were stained at 4 °C
and ﬁxed following washing with 2% paraformaldehyde. Data
acquisition was performed on a BD Biosciences FACSCalibur and
analysis was performed with WinList software (Verity Software
House).
Analysis of cytokine transcripts by RT-PCR
MDDCs were exposed to medium, LPS or CPXV+LPS; and total
RNA was extracted at 0, 1, 2, 4, 6, 12 and 24 h post-exposure using
RNeasy kit (Qiagen Inc, Valencia, CA). cDNA was synthesized using a
high-capacity reverse transcription kit (Applied Biosystems, Foster
City, CA) and used as a template for the quantitation of TNFα, MIP-1α
and IL-12p40 transcript levels using a Taqman® real-time RT-PCR
(Applied Biosystems). Transcript levels of either β-actin or cyclophilin
A were used as controls. The fold-change (2ΔΔCT) for each transcript
was calculated by normalizing CT values to control transcript levels at
each time-point followed by the normalization to CT values at 0 h for
each treatment.
Viral microarray
Viral microarray slides were printed in the UNM Experimental
Biology Laboratory (EBL) in accordance with their standard protocols
using a CPXV and VACV-speciﬁc oligo nucleotide library of 70-mers.
The oligonucleotide sequences were graciously provided by Dr.
Kathryn Sykes (Arizona State University) and are as described
(Borovkov et al., 2009). MDDCs were exposed to CPXV for 0, 0.5, 1,
2, 4 and 12 h. RNA was harvested using Trizol reagent (Invitrogen,
Carlsbad, CA) and cleaned to remove residual organics using the
RNeasyminikit (Qiagen, Valencia, CA). Amino allyl cRNA ampliﬁcation
and aRNA labeling with Cy3 were achieved using the MessageAmp™
II aRNA Ampliﬁcation Kit (Applied Biosystems/Ambion, Austin, TX) as
described by the manufacturer's protocols. Cy3-labeled aRNA was
hybridized to microarray slides in the UNM EBL. Microarray slides
were scanned to determine signal intensities of Cy3-labeled targets
using the GenePix 4000A scanner and data was collected using the
GenePix Pro 6 scanning, imaging and quantitation software. The data
set was normalized, ﬁltered, and clustered using Acuity. All software
and instrumentation was from Molecular Devices (Formerly Axon
Technologies, Sunnyvale, CA). Signiﬁcant gene expression differences
were determined by averaging the replicates at each time point. For
each CPXV-speciﬁc oligonucleotide representing a gene the average
signal at each time point was divided by the average signal at the 0 h
time to give a “fold over 0 time” expression value. Transcripts that
showed an increase of 2.5 fold or greater were considered signiﬁcant
for Table 3, but fold changes for all CPXV genes are recorded in
Supplemental Table 1, including those that did not achieve a 2.5 fold
increase above 0 time.
Western blot
5.0×105 infected MDDCs were harvested at indicated times,
washed with ice-cold PBS, then frozen quickly in liquid nitrogen and
lysed with ice-cold RIPA (Radio Immuno Precipitation Assay buffer)
buffer (150 mM NaCl, 1.0% NP-40 or Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.00) on ice for 30 min. Cell
lysates were centrifuged at 13,000 rpm for 10 min; and the protein
fraction was added to a loading buffer containing sodium dodecyl
sulfate (SDS) and 2× Laemmli buffer (4% SDS, 10% 2-mercaptoethanol,
20% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl) and boiledfor 5 min. Protein extracts were fractionated by electrophoresis in a
12% SDS-polyacrylamide gel (Bio-Rad Hercules, CA, USA) under
reducing conditions and transferred to a polyvinylidene diﬂuoride
membrane (PVDF, Bio-Rad Hercules). Membranes were blocked in 5%
nonfat milk in Tris-buffered saline, incubated for N2 h at RT or
overnight at 4 °C with an rabbit anti-CrmA polyclonal antibody,
washed, incubated with horseradish peroxidase-conjugated goat-
anti-rabbit IgG (Promega, Madison, WI, USA, W4011), probed using
enhanced chemiluminescence (ECL: Amersham, Little Chalfont,
England) and the autoradiograph captured on X-ray ﬁlm (Bio-Rad
Hercules).
Statistical analysis
Statistical analysis was performed as indicated in ﬁgure legends
using GraphPad Prism Software (GraphPad Software, Inc; San Diego,
CA).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.01.024.
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